Concepedia

David E. Stockett

DE

Statistics

Publications

6

Citations

456

H-Index

6

Active since

2003

Affiliations

Sunesis (United States)(Current)

University of California, San Francisco

David E. Stockett is an author at Sunesis (United States) specializing in pharmacology, medicine, and oncology.

Publications per year

2003–2010

6

Publications

6

Voreloxin Is an Anticancer Quinolone Derivative that Intercalates DNA and Poisons Topoisomerase II

Rachael E. Hawtin, David E. Stockett, Jo Ann W. Byl et al. · PLoS ONE · 2010 · 149 citations · Full text

, , +14

SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples

Andrew Conroy, David E. Stockett, Duncan Walker et al. · Cancer Chemotherapy and Pharmacology · 2009 · 125 citations · Full text

, , +6

SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo

Jennifer P. Arbitrario, Brian J. Belmont, Marc Evanchik et al. · Cancer Chemotherapy and Pharmacology · 2009 · 67 citations

, , +9

E-selectin up-regulation allows for targeted drug delivery in prostate cancer.

Vinay Bhaskar, Debbie A. Law, Eric Ibsen et al. · PubMed · 2003 · 65 citations

, , +15

Homologous recombination repair is essential for repair of vosaroxin-induced DNA double-strand breaks

Rachael E. Hawtin, David E. Stockett, Oi Kwan Wong et al. · Oncotarget · 2010 · 39 citations · Full text

, , +17

1–5 of 6